Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Dow
Johnson and Johnson
Merck
Chinese Patent Office
Moodys
Julphar
Boehringer Ingelheim
Express Scripts

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,273,876

« Back to Dashboard

Which drugs does patent 8,273,876 protect, and when does it expire?

Patent 8,273,876 protects LEVITRA and is included in one NDA.

This patent has forty-six patent family members in thirty-one countries.
Summary for Patent: 8,273,876
Title:Medicaments containing vardenafil hydrochloride trihydrate
Abstract: The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.
Inventor(s): Serno; Peter (Gladbach, DE), Grunenberg; Alfons (Dormagen, DE), Ohm; Andreas (Neuss, DE), Bellinghausen; Rainer (Odenthal, DE), Vollers; Eimer (Leverkusen, DE), Henck; Jan-Olav (Leverkusen, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:10/521,534
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,273,876

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-003 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-001 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-002 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-004 Aug 19, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,273,876

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 32 113Jul 16, 2002
PCT Information
PCT FiledJuly 03, 2003PCT Application Number:PCT/EP03/07093
PCT Publication Date:January 22, 2004PCT Publication Number: WO2004/006894

Non-Orange Book US Patents Family Members for Patent 8,273,876

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,841,446 Medicaments containing vardenafil hydrochloride trihydrate ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Federal Trade Commission
Chinese Patent Office
Medtronic
Baxter
Deloitte
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.